US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
biotech · Glioblastoma · Recurrent Brain Metastases · GTBP
GT Biopharma
GT Biopharma drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Brisbane, USA HQ
1973 Founded
8 Employees
Public company Type
GTBP · NYSE Ticker
Company details
- Status
- Public
- HQ
- Brisbane, USA
- Founded
- 1973
- Employees
- 8
- Programs
- 8
- Drugs
- 7
- Patents
- 1
GT Biopharma pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
GT Biopharma drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to GT Biopharma in public FDA and regional records.
-
Development asset linked to GT Biopharma in public FDA and regional records.
-
semaglutide
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.
- Target
- Glucagon-like peptide 1 receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist
-
Development asset linked to GT Biopharma in public FDA and regional records.
-
temozolomide
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to GT Biopharma in public FDA and regional records.